Navigation Links
SCOLR Pharma, Inc. Licenses Dietary Supplements
Date:12/1/2009

BOTHELL, Wash., Dec. 1 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (NYSE Amex: DDD) announced that on November 20, 2009 it licensed to Chrono Nutraceuticals LLC exclusive rights in Canada to manufacture and sell four extended release dietary supplements using SCOLR's proprietary CDT® drug delivery platform. In addition, SCOLR granted Chrono rights to manufacture and sell two of such products in the United States on a nonexclusive basis. Chrono paid SCOLR $25,000 upon execution of the agreement and agreed to pay SCOLR two additional payments of $87,500 each upon specified events related to regulatory approval for sales in Canada, but no later than April 30, 2010. Chrono also has the right to terminate the agreement and receive a refund of amounts paid to SCOLR within 90 days of the execution of the agreement under certain conditions related to such regulatory approvals. The agreement provides for royalties of 10% of net sales of the products covered by the license, and for minimum royalties of $125,000 per quarter commencing during the first quarter of 2010 (prorated based on commencement of sales) and increasing to $210,000 per quarter for 2011. The agreement is for a term of ten years with automatic renewal for additional five year terms provided that all payments are current.

Stephen J. Turner, SCOLR Pharma, Inc.'s Chief Executive Officer said, "The agreement with Chrono reflects our efforts to expand revenues from dietary supplement products and is indicative of the types of alliances we hope to add to support our future growth and operations. This agreement is an important step in increasing revenue sources to enable us to fund our operations. We continue to expand our product line and work with partners to open other distribution channels. At the same time we continue to pursue licensing opportunities and other stra
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards
2. SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
3. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
4. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
5. Northern Light Adds 4,000 Bio-Pharma, Health Sciences and General Business News and Journal Sources from EBSCO Publishing
6. Strativa Pharmaceuticals Development Partner, BioAlliance Pharma, Presents Phase III Study Results of Miconazole Lauriad(R) for the Treatment of Oropharyngeal Candidiasis
7. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
8. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
9. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
10. FluoroPharma, Inc. to Report Preclinical Data on Alzheimers Disease and Prostate Cancer PET Imaging Agents
11. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... 1, 2015  An innovative interventional radiology treatment ... sustained relief of their headaches, according to research ... Radiology ,s Annual Scientific Meeting . Clinicians ... New York Empire State College in Saratoga Springs ... (SPG) blocks to give patients enough ongoing relief ...
(Date:3/1/2015)... 2015  USPlabs has notified the Food and ... that media reports saying that a company product ... February 28, 2015, the Center for Drug Evaluation ... the contamination of a dietary supplement product labeled ... as "OEP") with a prescription drug active ingredient, ...
(Date:2/27/2015)... CHAPEL HILL, N.C. , Feb. 27, 2015 /PRNewswire/ ... the challenge of managing multiple products for the same ... especially for those that want to prevent one of ... of another.  According to recent research by ... promoted their products as independent brands rather than together ...
Breaking Medicine Technology:Image-guided treatment shown to break the migraine cycle 2Image-guided treatment shown to break the migraine cycle 3Image-guided treatment shown to break the migraine cycle 4OEP Product Is Counterfeit 2New Report Details How to Expand a Pharmaceutical Product Portfolio without Cannibalizing an Established Brand 2
... 28, 2011 Hotspur Technologies announced today that ... first clinical use of its Keeper™ Embolectomy Catheter. ... formation within arteries, while also incorporating the capability ... catheter. The Keeper Catheter combines a ...
... ShangPharma Corporation (NYSE: SHP ) ("ShangPharma" or ... and development outsourcing company, today announced that it will ... in New York from March 1 – 3, 2011. ... ShangPharma, will host a group presentation at 10:00 am ...
Cached Medicine Technology:Hotspur's Keeper Embolectomy Catheter Deployed for First Time 2ShangPharma to Present at the Citibank Global Health Care Conference from March 1 - 3, 2011 2
(Date:3/1/2015)... 02, 2015 Security Life Insurance ... benefits market, announced the addition of stand-alone individual ... Vision Insurance launched today, complete with two plan ... utilize the VSP® Vision Care network encompassing a ... practice space. The PrimeStar Select Vision plan will ...
(Date:3/1/2015)... 2015 Women’s Excellence now offers ... (OAB) symptoms, such as a strong need to urinate with ... medication (anticholinergic) does not work well enough or cannot be ... another approach to targeting the source of OAB, the bladder ... and bladder muscle, blocking the signals that trigger OAB. ...
(Date:3/1/2015)... March 01, 2015 Researchers say working ... so many sheet metal workers contract malignant mesothelioma. Surviving ... report on its website. Click here to read ... Construction Research and Training monitored 17,345 sheet metal workers ... number of them died of mesothelioma or another ...
(Date:3/1/2015)... New York, NY (PRWEB) March 01, 2015 ... ) has grown substantially over the past few weeks ... Liebhard LLP are actively filing claims, the Firm announces. ... 2015 reflects 7,713 cases in the Bergen County proceeding ... Ethicon Inc., compared with a few weeks earlier, when ...
(Date:3/1/2015)... 2015 “ The Barrel Mill ” was ... which takes a look at the latest and coolest technology ... of NewsWatch and a technology expert, conducted the review and ... to drinks. , According to Home Distillation of Alcohol, it's ... Well, there’s a pretty cool product that’ll help anyone achieve ...
Breaking Medicine News(10 mins):Health News:Security Life Insurance Company Launches Individual Vision Insurance Product 2Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2Health News:New Study Finds Indirect Asbestos Exposure Can Raise Mesothelioma Risk for Sheet Metal Workers, According to Surviving Mesothelioma 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2
... ... PhD, JD, is Keynote Speaker on the Failed War on Drugs , ... Las Vegas, NV (PRWEB) September 11, 2009 -- ... Drug Policy Alliance advocating for drug reform in the United States as keynote speaker former ...
... acoustic neuromas , FRIDAY, Sept. 11 (HealthDay News) -- Last ... or the sound of a dog barking. She was 22. ... type 2 (NF2), a condition characterized by tumors in the ... cranial nerve in one ear. , The result: increasing hearing ...
... affects insulin resistance, study finds, , FRIDAY, Sept. 11 (HealthDay ... insight into type 2 diabetes, potentially leading to better treatment ... appears to be linked to diabetes, affects how the body ... published Sept. 6 in Nature Genetics . , "Most ...
... Duane Reade Holdings Inc., the largest drug store in metropolitan New ... 2009 Komen New York City Race For The Cure, the Company, ... raised $330,000 to increase awareness of breast cancer and to assist ... year that Duane Reade has proudly sponsored this momentous event, with ...
... , , MADISON, N.J. and ... (FDA) today cleared the OVA1(TM) Test, the first blood test that, ... at risk for a malignant pelvic mass. OVA1 is the first ... with high sensitivity prior to biopsy or exploratory surgery, even if ...
... , , , ... Gardasil, declined by a third this year, and three years after ... women remain unvaccinated -- despite millions spent on advertising and lobbying ... , , Michelle Steward, assistant professor of marketing ...
Cached Medicine News:Health News:Healthcare Legal Issues Take the Stage at PAINWeek 2009 2Health News:Healthcare Legal Issues Take the Stage at PAINWeek 2009 3Health News:Cancer Drug Shrinks Benign Tumors That Steal Hearing 2Health News:Cancer Drug Shrinks Benign Tumors That Steal Hearing 3Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 2Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 3Health News:U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 2Health News:U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 3Health News:U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 4Health News:U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass 5Health News:HPV Vaccine Study Shows Why Few Women Getting Shots 2
... Graft, the newest vascular graft offering from ... in vascular surgical products for more than ... kinking and compression problems that can ... provides all of the benefits of a ...
... The drilling and rasping necessary in cruciate ... roughness on the bone surface. This condition, ... can damage the cruciate replacement. The GORE ... cruciate ligament reconstruction procedures. The tool functions ...
Vikingselect™ Intra-Operative Monitoring (IOM)....
... has been designed by practicing neurophysiologists ... the ever changing and demanding medical ... data from multiple modalities, including: SSEPs ... multiple patients at multiple sites. Our ...
Medicine Products: